Dopamine receptor D1 but not D3 essential for morphine-induced conditioned responses

Y.P. Wang¹, S.G. Wei¹, Y.S. Zhu¹, B. Zhao¹, X. Xun¹ and J.H. Lai¹,²

¹Key Laboratory of Forensic Science of Ministry of Public Health, Xi’an Jiaotong University, Xi’an, Shaanxi, China
²Key Laboratory of Environment and Genes Related to Diseases, Ministry of Education, Xi’an Jiaotong University, Xi’an, Shaanxi, China

Corresponding author: J.H. Lai
E-mail: laijh1011@mail.xjtu.edu.cn / wyp853@163.com

Received February 28, 2014
Accepted August 2, 2014
Published January 16, 2015
DOI http://dx.doi.org/10.4238/2015.January.16.1

ABSTRACT. Recent studies indicate the involvement of dopamine receptors D1 and D3 in the regulation of locomotor stimulant and conditioned responses to morphine in mice. Moreover, expression of brain-derived neurotrophic factor (BDNF) may be modulated by D1 and D3 receptor activities in the nucleus accumbens (NAc) and prefrontal cortex (PFC). However, the underlying interactions between D1 and D3 receptors and BDNF in the expression of behavioral responses controlled by drug-associated cues have not yet been fully elucidated. In this study, we used dopamine receptor mutant mice to explore the roles of the D1 and D3 receptors in locomotion and morphine-induced place preference; furthermore, we investigated the effects of morphine on BDNF expression in the NAc and PFC of the mouse brain. Our results show that D1 receptor but not D3 receptor mutant mice had decreased sensitivity to acute morphine-induced (10 mg/kg) locomotion (D1: $3814.82 \pm 319.9$ cm vs D3: $8089.64 \pm 967.4$ cm). Furthermore, D1 receptor mutant mice did not acquire morphine-conditioned place preference (D1: -18.3 ± 59.9, D3: 217.7 ± 64.1) and showed decreased
BDNF expression in the NAc (D1: 0.33 ± 0.07 fold, D3: 2.21 ± 0.18 fold) and PFC (D1: 0.74 ± 0.15 fold, D3: 1.68 ± 0.22 fold) compared with wild-type and D3 receptor mutant mice. These findings suggest that the D1 receptor is necessary for the induction of cue-associated morphine seeking and modulates locomotor habituation processes in response to acute morphine. The dopamine receptor D1 but not the D3 is also critical for morphine-induced BDNF expression in the NAc and PFC.

**Key words:** Morphine; Place preference; D1 receptor; D3 receptor; Brain-derived neurotrophic factor

**INTRODUCTION**

Drug addiction has been widely accepted as a chronic brain disorder and a disease of learning and memory (Wise, 2004). The mesolimbic dopamine (DA) pathway is involved in the control of motivational behavior, locomotor activity, reward, and the cognitive effects of several substances of abuse (Wise, 2004). Drugs of abuse can pathologically change neuronal circuits in the mesocorticolimbic DA system, which projects from the ventral tegmental area to the nucleus accumbens (NAc), prefrontal cortex (PFC) and other structures (Koob and Volkow, 2010). The PFC contributes to decision-making and the execution of goal-directed actions (Vertes, 2006). The NAc modulates motivation for drug seeking by integrating information from the PFC and relaying it to motor output structures, and in so doing, mediates reinforcement (Deadwyler et al., 2004).

DA modulates neurotransmission by acting at two classes of G protein-coupled receptors, termed D1-like (D1 and D5) and D2-like (D2, D3, and D4) receptors. These two classes of receptors are abundant in both the NAc and the PFC (Mansour et al., 1992; Diaz et al., 1995; Missale et al., 1998). In addition, there is substantial evidence that D1 and D3 receptors are particularly involved in the behavioral changes induced by drugs of abuse. D1 receptor agonists and antagonists have been found to modify drug-induced locomotor activity (Karlsson et al., 2008), responding rates (Katz et al., 1999), place preference (Pina and Cunningham, 2014) and heroin-seeking behavior (Tobin et al., 2013). We previously found that mice lacking the D1 receptor did not respond to cocaine-induced locomotor-stimulant effects (Xu et al., 1994a) and conditioned place preference (CPP) (Chen and Xu, 2010). In addition, some D3 receptor-preferring ligands alter morphine’s effects, including self-administration (David et al., 2002), morphine-induced hyperactivity (Manzanedo et al., 1999) and the establishment and expression of CPP (Vazquez et al., 2007). However, much research remains to be done to elucidate the underlying molecular mechanisms related to D1 and D3 receptors’ roles in morphine-related behaviors.

Brain-derived neurotrophic factor (BDNF) is a member of the neurotrophin family and is critically involved in the development, differentiation, maintenance, and survival of neurons (Blum and Konnerth, 2005). BDNF in the NAc and PFC may play an important role in the formation of drug-conditioned stimulus associations (Horger et al., 1999; Graham et al., 2007). Furthermore, previous studies have linked D1 and D3 receptor activation to increased BDNF expression and signaling (Kuppers and Beyer, 2001; Williams and Undieh, 2009; Liang et al., 2011); however, the underlying interactions between D1 and D3 receptors and BDNF in morphine-induced locomotion and place preference have not yet been established.

In this study, we used DA receptor mutant mice to further explore the roles of the D1
and D3 receptors in locomotion and morphine-induced place preference. We also investigated the effects of morphine on BDNF protein expression in the NAc and PFC of mouse brains. Our results show that the DA D1 receptor but not the D3 receptor is critical for cue-associated morphine-seeking and BDNF expression in specific areas of the brain.

**MATERIAL AND METHODS**

**Animals**

The DA D1 receptor mutant (\( D1^- \)) mice and DA D3 receptor mutant (\( D3^- \)) mice were generated by Xu et al. (1994a; 1997). The genotypes of the mice were identified using Southern blotting with gene-specific probes (Xu et al., 1994b). Male \( D1^- \), \( D3^- \) and wild-type (WT) mice (C57BL/6J, 12-14 weeks, 14-30 g) were housed in groups of four per cage at constant temperature (20°-22°C) and humidity (50-55%) under a 12 h light/dark cycle (lights on at 8:00 A.M.) with food and water *ad libitum*. The mice were allowed to habituate in the room for 7 days before the experimental manipulations. All experimental procedures were approved by the Animal Care and Use Committee of Xi’an Jiaotong University. All efforts were made to minimize the number of animals used and their suffering.

**Drug and antibodies**

Morphine hydrochloride was purchased from Sigma Chemical Co. (St. Louis, MO, USA) and dissolved in sterile saline. The morphine dose used in the current study was 1.0 mg/mL. All injections were administered intraperitoneally (ip) in a volume of 10 mL/kg body weight. The primary antibodies against BDNF were from Abcam Technology (Cambridge, MA, USA). The primary antibodies for β-actin and the horseradish peroxidase-conjugated anti-rabbit and anti-mouse secondary antibodies were purchased from Santa Cruz Technology (Santa Cruz, CA, USA).

**Behavioral tests**

To assess exploratory drive and anxiety- and depression-like behaviors in the \( D1^- \), \( D3^- \) and WT mice (\( N = 6 \) for each genotype), two behavioral assays were carried out.

**Open-field test**

A black square arena (45 cm x 45 cm x 30 cm) under homogenous illumination (150 Lux) was used. The arena was divided into a central zone (40% of the total area) and a peripheral zone (60% of the total area) (Prut and Belzung, 2003) by the video-tracking software (SMART, Panlab SL, Barcelona, Spain). Thirty minutes after a single dose of morphine, mice were placed in the peripheral zone and allowed to explore the apparatus freely for 15 min. Total distance, average velocity (locomotion), distance in the center zone and center zone entries were analyzed.

**Forced swim test**

Thirty minutes after receiving a morphine injection, mice were forced to swim in a Plexiglas cylinder (height 20 cm, diameter 19 cm) with water at a depth of 10 cm (25°C) for 10
min. Mouse performance in the cylinder was videotaped and scored by an observer blind to treatment condition. Immobility (depressive-like behavior) was defined as the absence of all movements except those movements necessary to keep the head above water (Schroeder et al., 2007).

**Conditioned place preference**

In a separate series of experiments, mice of each genotype were randomly assigned to three groups: the homecage group, the saline-treated group and the morphine-treated group (N = 5-6/group). The CPP apparatus consisted of two compartments (16.8 cm x 12.7 cm x 12.7 cm) that had different visual and tactile cues. One compartment was black with a stainless steel grid rod floor. The other compartment was white with a stainless steel mesh floor. The two compartments were separated by an opaque partition.

We used a biased CPP procedure similar to that described before (Chen and Xu, 2010) with modifications. During the preconditioning phase (day 1, pre-test), mice were placed in the CPP apparatus and were allowed to freely explore the two compartments for 15 min. The time spent in each compartment was recorded. Mice that spent more than 600 s of the 15 min period in either compartment or crossed between the compartments fewer than 20 times were excluded from analysis (4 of 54 mice). The next 12 days (days 2-13) comprised the conditioning and testing phases of the test. The morphine-treated group received an ip morphine injection (10 mg/kg body weight) and was confined to the white compartment for 40 min on day 2. On day 3, this group of mice received a volume-matched saline injection and was confined to the black compartment for 40 min. As a control, the saline group received ip saline injections on days 2 and 3 before being confined to each compartment. On day 4 (test 1), the mice were allowed to freely explore the three compartments for 15 min without injections, and the time spent in each compartment was recorded. Each mouse experienced four conditioning sessions (days 5-6, 8-9, 11-12) and testing sessions (days 7, 10, 13). The mice were sacrificed by decapitation immediately after test 4 (day 13), and brain tissues from the NAc and PFC were dissected out and stored at -80°C until used for assay.

**Protein extraction and immunoblotting**

The brain samples were homogenized in 50 mM radio immunoprecipitation assay buffer (20μL/mg) containing a protease inhibitor cocktail and phosphatase inhibitor cocktail. The homogenates were incubated on ice for 30 min and centrifuged at 12,000 g for 15 min at 4°C. The protein content was determined using the bicinchoninic acid method (Joincare Co., Zhuhai, China). The protein samples were mixed with equal volumes of electrophoresis loading buffer, denatured and stored at -80°C until ready to be used. Then, the samples, which contained 15 μg of total protein, were denatured at 95°C for 5 min, separated by 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to poly-vinylidene fluoride membranes. The membranes were blocked with 5% non-fat milk in Tris-buffered saline (500 mM NaCl, 20 mM Tris-HCl, pH 7.5) containing 0.05% Tween-20 for 1 h. The membranes were incubated with primary antibodies against BDNF or β-actin (Abcam, MA, USA), gently agitated overnight at 4°C, incubated with anti-rabbit or anti-mouse secondary antibody conjugated to horseradish peroxidase and developed using enhanced chemiluminescence (Millipore, MA, USA). The bands were normalized to β-actin. All Western blot analyses were performed at least three times, and parallel results were obtained. The autoradiogram bands of the BDNF
proteins in the PFC and NAc were analyzed using the Image-Pro Plus program. The integrated optical densities of protein bands were compared to determine their levels of expression.

Data analysis

All data are reported as means ± SE. The data were analyzed using a two-way ANOVA followed by Bonferroni’s post hoc test. The CPP scores were expressed as time spent on the saline-paired side subtracted from time spent on the morphine-paired side. The results from the Western blot were analyzed using densitometry. The ratio of BDNF to β-actin was calculated for each sample. The homecage controls were set at 1. Values of P < 0.05 were considered to be statistically significant.

RESULTS

Dopamine D1 receptor but not D3 receptor mutant mice showed decreased sensitivity to morphine-induced locomotor effects

A two-way ANOVA of total distance traveled in the open-field test (OFT) revealed a significant genotype effect [Figure 1A, F(genotype,2,30) = 35.61, P < 0.001]. In the open-field arena, the WT and D3−/− mice showed significantly enhanced locomotor activity after acute morphine administration (post hoc tests, both P < 0.0001). No significant change in total distance was observed in the D1−/− mice. Furthermore, distance traveled in the central zone was also significantly affected by genotype [Figure 1B F(genotype,2,30) = 8.930, P < 0.01] and morphine treatment [F(treatment,1,30) = 6.099, P < 0.05]. Subsequent post hoc tests indicated that morphine significantly decreased distance traveled in the central zone in both the WT and D3−/− mice (P < 0.05 and P < 0.0001, respectively). However, no significant change in central distance was observed in the D1−/− mice after morphine injection. There was no difference in average velocity (Figure 1C), center zone entries (Figure 1D) or immobility time (Figure 2) between the three genotypes of mice following morphine treatment.

Figure 1. Morphine-induced locomotor behaviors in dopamine receptor D1 (D1−) or D3 (D3−) mutant mice. The D1− but not the D3− mice showed decreased sensitivity to morphine-induced locomotor effects. The D1− and D3− receptor mutant mice (N = 6/group) were given a single dose of morphine (10.0 mg/kg) intraperitoneally and subjected to an open-field test. (A) Total distance, (B) center zone distance, (C) average velocity and (D) center zone entries were analyzed. Values are reported as means ± SE. *P < 0.05; ***P < 0.0001 vs saline controls of the same genotype. WT = wild-type mice.
Morphine-induced effects on immobility in dopamine D1 (D1<sup>−/−</sup>) and D3 (D3<sup>−/−</sup>) receptor mutant mice. D1<sup>−/−</sup> and D3<sup>−/−</sup> mice (N = 6/group) were given a single dose of morphine (10.0 mg/kg) intraperitoneally and subjected to a forced swim test during which time spent immobile was measured. WT = wild-type mice.

DA D1 receptor mutant mice do not acquire morphine-induced CPP

Next, we investigated the role of the D1 and D3 receptors in the rewarding effects of morphine at the dose of 1.0 mg/kg (Figure 3). No significant difference was observed in basal CPP score (pretest) between the three genotypes of mice. In test 2, there was a significant effect of treatment \[ F_{\text{treatment}} (1,30) = 10.78, P < 0.01 \] but not genotype \[ F_{\text{genotype}} (2,30) = 2.246, P = 0.123 \] after conditioning. Furthermore, the morphine-paired D3<sup>−/−</sup> mice showed a significant CPP (P < 0.05) and the WT mice showed a nearly significant CPP (P = 0.0543) compared with their saline-paired counterparts. Following four conditioning sessions (test 4), the analysis revealed a significant effect of both treatment and genotype \[ F_{\text{treatment}} (1,30) = 9.607, P < 0.01; F_{\text{genotype}} (2,30) = 6.77, P < 0.05 \] as well as their interaction \[ F_{\text{treatment x genotype}} (2,30) = 3.504, P < 0.05 \] on CPP scores. The post hoc comparisons indicated that both the D3<sup>−/−</sup> and WT mice developed CPP after conditioning (D3<sup>−/−</sup>: P < 0.0001; WT: P < 0.05) compared with their saline-paired controls, whereas the D1<sup>−/−</sup> mice did not (P = 0.126). The D1<sup>−/−</sup>, D3<sup>−/−</sup> and WT mice did not show CPP acquisition with saline injections throughout the experiment, indicating that the injection itself does not affect place preference.

The DA D1 receptor but not the D3 receptor is critical for morphine-induced BDNF expression in the NAc and PFC

Because D1<sup>−/−</sup> mice do not readily acquire morphine-induced CPP, we next investigated whether there is a corresponding change in BDNF protein expression in the NAc and PFC in the D1 and D3 receptor mutant mice. An ANOVA of BDNF expression in the NAc showed a significant genotype effect \[ F_{\text{genotype}} (2,45) = 27.33, P < 0.0001 \], treatment effect \[ F_{\text{treatment}} (2,45) = 22.65, P < 0.0001 \] and genotype x treatment interaction \[ F_{\text{treatment x genotype}} (4,45) = 21.48, P < 0.0001 \] (Figure 4A). The post hoc comparisons showed a significant increase in BDNF in the NAc in both the morphine-paired WT and D3<sup>−/−</sup> mice (compared with homecage, both P < 0.0001) after CPP acquisition. In contrast, an obvious decrease in BDNF was observed in the D1<sup>−/−</sup> mice.
in the NAc of the $D1^{-/-}$ mice ($P < 0.05$). In the PFC, there was a significant effect of genotype [$F_{\text{genotype}}(2,45) = 5.232, P < 0.01$], treatment [$F_{\text{treatment}}(2,45) = 7.522, P < 0.01$] and a strong genotype x treatment interaction [$F_{\text{treatment x genotype}}(4,45) = 7.801, P < 0.0001$] on BDNF levels (Figure 4B). Increased BDNF levels were found in both the morphine-paired WT and $D3^{-/-}$ mice (post hoc tests, both $P < 0.05$, compared with homecage) with no obvious change in the $D1^{-/-}$ mice. BDNF expression was similar in both brain regions between all genotypes following saline treatment.

Figure 3. Dopamine D1 ($D1^{-/-}$) receptor mutant mice do not acquire morphine-induced CPP. The $D1^{-/-}, D3^{-/-}$ and wild-type (WT) mice received repeated injections alternating between morphine (10.0 mg/kg) and saline (N = 5-6/group) and were confined to CPP chambers. The mice were then tested for their place preference without injections at the indicated time points. The CPP scores represent time spent on the drug-paired side minus time on the saline-paired side. *$P < 0.05$; ***$P < 0.0001$ vs saline controls of the same genotype. WT = wild-type mice.

Figure 4. Morphine-induced BDNF expression. BDNF expression in the (A) NAc and (B) PFC of dopamine D1 ($D1^{-/-}$) and D3 ($D3^{-/-}$) receptor mutant mice were determined by Western blot. The mice were sacrificed at the end of the fourth CPP test. Data are reported as means ± SE relative to the WT saline controls that were set as 1. $\beta$-actin levels were used as a loading control. *$P < 0.05$; ***$P < 0.0001$ compared with the saline control group of the same genotype. Hc = homecage control; Sal = saline-injected; Mor = morphine-injected; WT = wild-type mice.
DISCUSSION

The aim of the present study was to explore the roles of D1 and D3 receptors in morphine-stimulated locomotion and reward-related behaviors, and further, to investigate the effects of morphine on BDNF protein expression in specific regions of the mouse brain such as the NAc and PFC. We found that mice lacking the D1 receptor but not the D3 receptor demonstrated reduced locomotor activity in response to acute morphine. The OFT is commonly used to assess the sedative, toxic, or stimulant effects of compounds. It is based on the natural tendency of an animal to explore and use the avoidance reaction to protect itself, which makes normal animals spend more time in the corners and the periphery than in the center (the most anxiogenic area) (Choleris et al., 2001). An increase in activity in the central zone during the test likely reflects various aspects of emotionality, including decreased anxiety and increased exploratory drive (Wang et al., 2012). Rezayof et al. (2013) demonstrated in the elevated plus-maze that ip administration of morphine (5, 7.5, and 10 mg/kg) increased the percentage of open arm time and open arm entries, suggesting an anxiolytic-like response to morphine. In the present study, four behavioral parameters were analyzed: total distance and average velocity reflect locomotor activity, while reduced center distance and center entries reflect anxiety-like behavior. The results of the OFT showed that morphine exerted locomotor stimulant effects on the WT and D3−/− mice. Locomotor effects were not observed in the D1−/− mice, indicating a critical role for the DA D1 receptor in modulating sensitivity to morphine-induced locomotion.

It is known that environmental stimuli (people, places, and things) associated with drug use can trigger intense cravings in addicted patients (Dackis and O’Brien, 2005). Among the various experimental protocols that have been used to measure the rewarding effects of drugs in laboratory animals, CPP has been one of the most popular. CPP appears to reflect a preference for a context due to the contiguous association between the context and a drug stimulus (Bardo and Bevins, 2000). One major finding of our study was the reduction in morphine reward sensitivity in mice lacking the D1 but not the D3 receptor. Previous research showed that the D1 and D3 receptors are differentially involved in learning associations between cues and the rewarding properties of drugs of abuse. The D1−/− mice failed to acquire CPP, whereas the D3−/− mutant mice show a delayed CPP extinction compared with WT mice (Chen and Xu, 2010). The intra-hippocampal administration of the D1 receptor antagonist SCH 23390 can block morphine-induced CPP and significantly decrease intra-VTA morphine-induced CPP (Esmaeili et al., 2012). Furthermore, the D3−/− mice showed a similar morphine CPP induction to that of the WT mice, which is also in agreement with previous findings (Karasinska et al., 2005).

We previously reported that the BDNF protein levels were significantly decreased in the PFC of the D1−/− mice, whereas no changes were found in the D3−/− mice (Xing et al., 2012). Furthermore, Williams and Undieh (2009) showed that the D1 receptor agonist SKF38393 can produce a significant increase in BDNF protein levels in striatal and hippocampal tissue slices. These findings suggest that the induction of BDNF expression may constitute a downstream response to D1-like dopamine receptor activation. In the present study, we demonstrated that the DA D1 receptor but not the D3 receptor is necessary for morphine-induced BDNF expression in the NAc and PFC. After morphine conditioning, the D1−/− mice showed significantly decreased BDNF expression in the NAc and PFC compared with WT and D3−/− mice. Similarly, Pina and Cunningham (2012) demonstrated that the blockade of the DA D1 but not D2 receptor impairs the development of ethanol-induced CPP. In the case of cocaine, the levels of...
striatal BDNF and its receptor TrkB were significantly higher in mice following prenatal cocaine or D1 agonist treatment (Tropea et al., 2011). Furthermore, D3−/− mice showed a delayed cocaine-CPP extinction and sustained extracellular regulated protein kinases activation, which is thought to be an upstream signal of BDNF expression, in the NAc and PFC compared with WT mice (Chen and Xu, 2010). These studies all support the notion that the DA D1 receptor but not the D3 receptor modulates BDNF expression in different brain regions during the acquisition of cue-associated morphine seeking.

In conclusion, these findings suggest that the D1 receptor is necessary for the induction of cue-associated morphine seeking and modulates locomotor habituation processes in response to acute morphine. Moreover, our results suggest that the DA D1 receptor but not the D3 receptor is critical for morphine-induced BDNF expression in the NAc and PFC.

ACKNOWLEDGMENTS

Research supported by the National Science Foundation of China (#NSFC 31271340).

REFERENCES

Kuppers E and Beyer C (2001). Dopamine regulates brain-derived neurotrophic factor (BDNF) expression in cultured...